Terms ending in 2033
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,919,950 | Expression Vector Encoding Antibody Molecule Which Binds IL-17A and IL-17F In force · Medium confidence | Ucb Biopharma SRL | In force | Medium confidence | |
| US 10,221,251 | Sequence Symmetric Modified IGG4 Bispecific Antibodies In force · Medium confidence | Ucb Biopharma SRL | In force | Medium confidence | |
| US 10,562,966 | Antibodies of the Class IGG4 In force · Medium confidence | Ucb Biopharma SRL | In force | Medium confidence | |
| US 9,803,004 | Albumin Binding Antibodies and Binding Fragments Thereof In force · Medium confidence | Ucb Biopharma SPRL | In force | Medium confidence | |
| US 11,466,324 | Lipocalin 2 as a Biomarker for IL-17 Inhibitor Therapy Efficacy In force · Medium confidence | Ucb Biopharma SPRL | In force | Medium confidence | |
| US 9,808,575 | Auto-Injector In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| US 10,799,583 | Treatment for Bone Diseases In force · Medium confidence | Ucb Pharma, S.A. | In force | Medium confidence | |
| US 12,667,615 | Treatment for Bone Diseases In force · Medium confidence | Ucb Pharma S.A. | In force | Medium confidence | |
| US 9,795,734 | Auto-Injector In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| US 11,059,911 | Sequence Symmetric Modified IGG4 Bispecific Antibodies In force · Medium confidence | Ucb Biopharma SRL | In force | Medium confidence | |
| 4 more term ends in 2033 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
3 of these are in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.